CTLA4 and neoplasm: Recent findings also suggest that many of the anti-CTLA-4 antibodies with the anti-tumor activity, including ipilimumab (a fully human anti-human CTLA-4 monoclonal antibody of the IgG1 subclass), might not be acting simply as the checkpoint blocker.